Anti-VEGF Agents for the Treatment of Pigment Epithelial Detachments Associated with Neovascular Age-related Macular Degeneration: An Evidence-based Approach.
作者信息
Panos Georgios D, Gatzioufas Zisis
机构信息
Department of Ophthalmology, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Department of Ophthalmology, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Geneva, Switzerland ; Moorfields Eye Hospital, London, UK.
出版信息
Med Hypothesis Discov Innov Ophthalmol. 2015 Winter;4(4):127-129.
Abstract
摘要
相似文献
1
Anti-VEGF Agents for the Treatment of Pigment Epithelial Detachments Associated with Neovascular Age-related Macular Degeneration: An Evidence-based Approach.
Med Hypothesis Discov Innov Ophthalmol. 2015 Winter;4(4):127-129.
2
OPTIMAL MANAGEMENT OF PIGMENT EPITHELIAL DETACHMENTS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Retina. 2018 Nov;38(11):2103-2117. doi: 10.1097/IAE.0000000000002195.
3
Serous Index of Pigment Epithelial Detachments in Neovascular Age-Related Macular Degeneration Predicts Response to Anti-Vascular Endothelial Growth Factor Treatment.
Ophthalmic Surg Lasers Imaging Retina. 2015 Jul-Aug;46(7):724-7. doi: 10.3928/23258160-20150730-06.
4
[Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study].
J Fr Ophtalmol. 2009 May;32(5):309-13. doi: 10.1016/j.jfo.2009.04.001. Epub 2009 May 17.
5
Imaging characteristics of neovascular pigment epithelial detachments and their response to anti-vascular endothelial growth factor therapy.
Br J Ophthalmol. 2013 Aug;97(8):1024-31. doi: 10.1136/bjophthalmol-2013-303155. Epub 2013 Jun 12.
6
Indocyanine green videoangiographic findings in detachment of the retinal pigment epithelium.
Ophthalmology. 1995 Apr;102(4):622-9. doi: 10.1016/s0161-6420(95)30990-6.
7
TYPE 1 VERSUS TYPE 3 NEOVASCULARIZATION IN PIGMENT EPITHELIAL DETACHMENTS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: A Prospective Study.
Retina. 2016 Dec;36 Suppl 1:S50-S64. doi: 10.1097/IAE.0000000000001271.
8
Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment.
Semin Ophthalmol. 2017;32(3):309-315. doi: 10.3109/08820538.2015.1072222. Epub 2015 Sep 4.
9
Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
Br J Ophthalmol. 2017 Jul;101(7):970-975. doi: 10.1136/bjophthalmol-2016-309434. Epub 2016 Dec 2.
10
VOLUMETRIC ASSESSMENT OF THE RESPONSIVENESS OF PIGMENT EPITHELIAL DETACHMENTS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TO INTRAVITREAL BEVACIZUMAB.
Retina. 2016 Feb;36(2):264-71. doi: 10.1097/IAE.0000000000000795.
引用本文的文献
1
Longitudinal changes in pigment epithelial detachment composition indices (PEDCI): new biomarkers in neovascular age-related macular degeneration.
Graefes Arch Clin Exp Ophthalmol. 2024 May;262(5):1489-1498. doi: 10.1007/s00417-023-06335-3. Epub 2023 Dec 23.
本文引用的文献
1
Ranibizumab for the treatment of degenerative ocular conditions.
Clin Ophthalmol. 2014 Jun 24;8:1187-98. doi: 10.2147/OPTH.S40350. eCollection 2014.
2
Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.
Biomed Res Int. 2014;2014:273754. doi: 10.1155/2014/273754. Epub 2014 May 7.
3
Ranibizumab treatment for choroidal neovascularization secondary to causes other than age-related macular degeneration with good baseline visual acuity.
Semin Ophthalmol. 2014 Mar;29(2):108-13. doi: 10.3109/08820538.2013.839716. Epub 2014 Jan 10.
4
Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration.
Drug Des Devel Ther. 2013 Jul 10;7:565-9. doi: 10.2147/DDDT.S46610. Print 2013.
5
Intravitreal ranibizumab in choroidal neovascularisation due to multifocal choroiditis and panuveitis syndrome.
BMJ Case Rep. 2013 Jul 17;2013:bcr2013009572. doi: 10.1136/bcr-2013-009572.
6
Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab.
Eye (Lond). 2013 May;27(5):663-7; quiz 668. doi: 10.1038/eye.2013.31. Epub 2013 Apr 5.
7
Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy.
Retina. 2013 May;33(5):990-7. doi: 10.1097/IAE.0b013e3182755793.
8
Topical ranibizumab as a treatment of corneal neovascularization.
Cornea. 2013 Jul;32(7):992-7. doi: 10.1097/ICO.0b013e3182775f8d.
9
Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence.
Graefes Arch Clin Exp Ophthalmol. 2012 Sep;250(9):1283-92. doi: 10.1007/s00417-012-1955-2. Epub 2012 Feb 21.
10
One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration.
Eye (Lond). 2011 Aug;25(8):1034-8. doi: 10.1038/eye.2011.115. Epub 2011 May 20.
Zotero 插件